Annual CFO
-$128.41 M
+$16.67 M+11.49%
December 31, 2024
Summary
- As of February 23, 2025, AXSM annual cash flow from operations is -$128.41 million, with the most recent change of +$16.67 million (+11.49%) on December 31, 2024.
- During the last 3 years, AXSM annual CFO has fallen by -$20.18 million (-18.65%).
- AXSM annual CFO is now -7772.60% below its all-time high of -$1.63 million, reached on December 31, 2013.
Performance
AXSM Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
N/A
December 31, 2024
Summary
- AXSM quarterly cash flow from operations is not available.
Performance
AXSM Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFO
N/A
December 31, 2024
Summary
- AXSM TTM cash flow from operations is not available.
Performance
AXSM TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
AXSM Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +11.5% | - | - |
| 3 y3 years | -18.6% | - | - |
| 5 y5 years | -176.9% | - | - |
AXSM Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -18.6% | +11.5% | ||||
| 5 y | 5-year | -176.9% | +11.5% | ||||
| alltime | all time | -7772.6% | +11.5% |
Axsome Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$128.41 M(-11.5%) | - | - |
| Sep 2024 | - | -$18.63 M(-38.1%) | -$132.57 M(-20.8%) |
| Jun 2024 | - | -$30.11 M(-43.7%) | -$167.49 M(-13.1%) |
| Mar 2024 | - | -$53.47 M(+76.1%) | -$192.73 M(+32.8%) |
| Dec 2023 | -$145.08 M(+24.5%) | -$30.36 M(-43.3%) | -$145.08 M(+2.0%) |
| Sep 2023 | - | -$53.55 M(-3.3%) | -$142.28 M(+27.6%) |
| Jun 2023 | - | -$55.35 M(+850.9%) | -$111.49 M(+24.3%) |
| Mar 2023 | - | -$5.82 M(-78.9%) | -$89.68 M(-23.0%) |
| Dec 2022 | -$116.51 M(+7.7%) | -$27.56 M(+21.1%) | -$116.51 M(-1.1%) |
| Sep 2022 | - | -$22.76 M(-32.1%) | -$117.79 M(-3.3%) |
| Jun 2022 | - | -$33.54 M(+2.7%) | -$121.81 M(+7.2%) |
| Mar 2022 | - | -$32.65 M(+13.2%) | -$113.66 M(+5.0%) |
| Dec 2021 | -$108.23 M(+37.9%) | -$28.84 M(+7.7%) | -$108.23 M(+8.3%) |
| Sep 2021 | - | -$26.78 M(+5.4%) | -$99.94 M(+12.4%) |
| Jun 2021 | - | -$25.39 M(-6.7%) | -$88.90 M(+7.9%) |
| Mar 2021 | - | -$27.22 M(+32.4%) | -$82.40 M(+5.0%) |
| Dec 2020 | -$78.46 M(+69.2%) | -$20.55 M(+30.6%) | -$78.46 M(+4.0%) |
| Sep 2020 | - | -$15.73 M(-16.7%) | -$75.47 M(+7.3%) |
| Jun 2020 | - | -$18.90 M(-18.8%) | -$70.36 M(+17.0%) |
| Mar 2020 | - | -$23.27 M(+32.5%) | -$60.15 M(+29.7%) |
| Dec 2019 | -$46.38 M | -$17.57 M(+65.3%) | -$46.38 M(+20.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | - | -$10.63 M(+22.4%) | -$38.60 M(+13.9%) |
| Jun 2019 | - | -$8.68 M(-8.6%) | -$33.89 M(+3.1%) |
| Mar 2019 | - | -$9.50 M(-3.0%) | -$32.87 M(+9.4%) |
| Dec 2018 | -$30.05 M(+13.5%) | -$9.79 M(+65.7%) | -$30.05 M(+13.2%) |
| Sep 2018 | - | -$5.91 M(-22.9%) | -$26.55 M(-2.0%) |
| Jun 2018 | - | -$7.67 M(+14.8%) | -$27.09 M(+2.2%) |
| Mar 2018 | - | -$6.68 M(+6.2%) | -$26.52 M(+0.2%) |
| Dec 2017 | -$26.47 M(+24.4%) | -$6.29 M(-2.4%) | -$26.47 M(-3.4%) |
| Sep 2017 | - | -$6.45 M(-9.1%) | -$27.40 M(+6.4%) |
| Jun 2017 | - | -$7.10 M(+6.9%) | -$25.75 M(+7.4%) |
| Mar 2017 | - | -$6.64 M(-8.0%) | -$23.97 M(+12.6%) |
| Dec 2016 | -$21.28 M(+186.1%) | -$7.22 M(+50.3%) | -$21.28 M(+30.4%) |
| Sep 2016 | - | -$4.80 M(-9.6%) | -$16.32 M(+21.4%) |
| Jun 2016 | - | -$5.31 M(+34.6%) | -$13.44 M(+31.4%) |
| Mar 2016 | - | -$3.95 M(+75.4%) | -$10.23 M(+37.5%) |
| Dec 2015 | -$7.44 M(+61.8%) | -$2.25 M(+17.1%) | -$7.44 M(+43.4%) |
| Sep 2015 | - | -$1.92 M(-8.7%) | -$5.19 M(+58.9%) |
| Jun 2015 | - | -$2.11 M(+81.8%) | -$3.27 M(+181.8%) |
| Mar 2015 | - | -$1.16 M | -$1.16 M |
| Dec 2014 | -$4.60 M(+181.8%) | - | - |
| Dec 2013 | -$1.63 M | - | - |
FAQ
- What is Axsome Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Axsome Therapeutics?
- What is Axsome Therapeutics annual CFO year-on-year change?
- What is the all time high quarterly CFO for Axsome Therapeutics?
- What is the all time high TTM CFO for Axsome Therapeutics?
What is Axsome Therapeutics annual cash flow from operations?
The current annual CFO of AXSM is -$128.41 M
What is the all time high annual CFO for Axsome Therapeutics?
Axsome Therapeutics all-time high annual cash flow from operations is -$1.63 M
What is Axsome Therapeutics annual CFO year-on-year change?
Over the past year, AXSM annual cash flow from operations has changed by +$16.67 M (+11.49%)
What is the all time high quarterly CFO for Axsome Therapeutics?
Axsome Therapeutics all-time high quarterly cash flow from operations is -$1.16 M
What is the all time high TTM CFO for Axsome Therapeutics?
Axsome Therapeutics all-time high TTM cash flow from operations is -$1.16 M